Ozempic Personality With Dr Spencer Nadolsky

Ozempic Personality With Dr Spencer Nadolsky

This conversation dives headfirst into one of the most controversial and least understood side effects of GLP-1 medications, what many are now calling the “Ozempic personality.” In this candid interview, Dr. Spencer Nadolsky joins On The Pen to unpack the growing reports of anhedonia, a flattening of motivation, desire, and emotional highs that some patients experience, especially at higher doses of tirzepatide and similar therapies.


What starts as a discussion about how these medications work in the brain quickly turns into something much deeper. We explore how GLP-1 and GIP receptor agonists don’t just reduce hunger, they fundamentally alter the brain’s reward system, dampening cravings, food noise, and in some cases, the very drive to seek pleasure at all. That is where the idea of the “Ozempic personality” begins to take shape, not as a diagnosis, but as a shared patient experience that is only now being taken seriously.


Dave opens up about his own journey, spending years at the highest dose and slowly realizing that while the medication gave him control over food and blood sugar, it also quietly muted parts of his identity. Hobbies faded. Motivation shifted. The highs and lows of life became more… flat. And it wasn’t until stepping away that he could see the contrast clearly.


Dr. Nadolsky brings clinical perspective to match the lived experience, explaining how this isn’t classic depression, but something more nuanced. Patients aren’t necessarily sad, they just stop wanting things. He shares how often this shows up in his practice, how he identifies it, and most importantly, how adjusting dose rather than stopping treatment altogether can restore balance.


The conversation also raises bigger questions about transparency in clinical trials, what drug companies knew about these “anti-hedonic” effects, and why something so impactful may not have been formally tracked. At the same time, both Dave and Dr. Nadolsky emphasize what matters most, these medications are still life changing, even life saving, but they are not one size fits all.


If you’ve ever felt like something changed beyond just your appetite while on a GLP-1, this is the conversation you’ve been waiting for. It puts language to an experience thousands are having but struggling to explain, and it gives you something even more important, a path forward.


Watch the full interview to understand the reality behind the “Ozempic personality,” how to recognize it, and how to work with your doctor to find your own sweet spot.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(197)

How To Get $50 GLP-1

How To Get $50 GLP-1

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode o...

23 Kesä 44min

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ​⁠ to break down the molecules, clinica...

16 Kesä 1h 15min

Retatrutide Just Reached Bariatric Surgery Results

Retatrutide Just Reached Bariatric Surgery Results

Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference....

11 Kesä 48min

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

9 Kesä 20min

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...

2 Kesä 20min

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

https://linktr.ee/manonthemounjaro

26 Touko 30min

Lilly Bets $8B on Weight Loss Future

Lilly Bets $8B on Weight Loss Future

https://linktr.ee/manonthemounjaro

19 Touko 23min

The Next Two Weeks in GLP1 Are Huge, Here's Why

The Next Two Weeks in GLP1 Are Huge, Here's Why

http://www.otplinks.com

12 Touko 1h 7min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
rss-pitaisko-erota
tiedenaiset-podcast
psykopodiaa-podcast
meditaatiot-suomeksi
vakeva-elama-viisaampi-mieli-vahvempi-keho
rss-narsisti
rss-kuumilla-aalloilla
junnut-pelissa
terapiassa
katilon-kahvitunti
voi-hyvin-meditaatiot-2
rss-uplevel-by-sonja-hannus
rss-pt-paahtio
rss-eropodi
rss-kehtaanko-kysya-podcast-aideille
rss-pska-juttu
rss-nautinto
selviytyjat-tarinoita-elamasta
fitnessvastaanotto